Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such ...

April 1, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that a Phase II Clinical Trial of ...

Researchers also reported results from a separate trial of a gene therapy the company is developing for PKP2-related arrhythmogenic cardiomyopathy.

Alfasigma saw double-digit growth from many of its brands namely Vessel®, Normix® and Jyseleca® and the Esoxx (reflux) brand family. Similarly, Alfasigma saw significant growth across its Growth ...

Survival outcomes (mPFS 8.2 months; 12-month OS 80.8%) compare favorably with typical first-line chemo-immunotherapy ...

Detailed price information for Candel Therapeutics Inc (CADL-Q) from The Globe and Mail including charting and trades.

Pritelivir met its primary endpoint of superior lesion healing, achieving a 62.7% lesion healing rate compared to 34.0% with standard-of-care therapies (investigator’s choice), resulting in an ...

The National Security Agency has published Phase One and Phase Two of its Zero Trust Implementation Guidelines, or ZIGs, to provide organizations with activities needed to advance their cybersecurity ...

bAirway Research Center North, German Center for Lung Research, LungenClinic Grosshansdorf and Christian Albrechts University of Kiel, Kiel, Germany cSection on Pulmonary and Critical Care Medicine, ...

President Donald Trump’s administration formally launched the second phase of its plan to end the war between Israel and Hamas this week, shifting from a ceasefire framework toward a post-ceasefire ...

SANYO DENKI SanMotion's Products' SM series 2-phase stepping motors achieve excellent torque performance and high efficiency. SANYO DENKI SanMotion Products' F2 56 mm sq. 2-phase stepping motors offer ...